logo

Human Insulin Drugs Market Size (2024 - 2029)

The Human Insulin Drugs Market is projected to experience growth over the forecast period, driven by the increasing healthcare needs of diabetes patients, particularly those affected by COVID-19. The pandemic has exacerbated challenges for individuals with diabetes, who are at a higher risk of severe complications due to weakened immune systems. This has led to increased healthcare expenses and a heightened demand for insulin management solutions. As patients, especially those with Type 2 diabetes, require frequent adjustments to maintain blood glucose levels, the market is expected to expand to meet these needs.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Hyperglycemics Research Insulin Market Market Size

Market Size of Human Insulin Drugs Industry

Insulin Drugs Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 27.96 Billion
Market Size (2029) USD 33.81 Billion
CAGR (2024 - 2029) 3.87 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Clinical Laboratory Services Market Major Players

*Disclaimer: Major Players sorted in no particular order

Insulin Drugs Market Analysis

The Human Insulin Drugs Market size is estimated at USD 27.96 billion in 2024, and is expected to reach USD 33.81 billion by 2029, growing at a CAGR of 3.87% during the forecast period (2024-2029).

The factors driving the Insulin Market include the rising prevalence of diabetes, the increasing number of novel insulin product launches, and growing government initiatives to create awareness about diabetes.

Diabetes is a chronic (long-lasting) health condition that affects insulin-mediated glucose intake into the cells. Hence, diabetes patients must take insulin daily to maintain blood glucose levels. The rising prevalence of diabetes cases propels the growth of the Human Insulin Market. For instance, according to a 2022 update from the International Diabetic Federation (IDF), the number of individuals living with diabetes is estimated to reach 643 million by 2030 and 783 million by 2045. The significant increase in diabetes and the massive role of insulin in managing this disease is expected to boost the growth of the Global Insulin Market over the forecast period.

The growing government initiatives to create awareness about diabetes and insulin use are also expected to drive the Insulin Market during the forecast period. In November 2023, WHO launched a campaign with an Access to Diabetes Care theme to raise awareness about diabetes and minimize the risk of complications by detection and proper treatment. Raising awareness about diabetes prevention and treatment options is expected to drive the Insulin Market.

The development of various insulin delivery systems is anticipated to boost market growth. For instance, in March 2024, researchers funded by the EU are working on an alternative method to deliver insulin without needles, contributing to the Non-Injectable Insulin Market. The project, called BuBble Gun, aims to deposit liquids into the skin and other soft tissues using compression. This five-year project, slated to conclude by the end of 2024, seeks to develop a needle-free insulin delivery system. These Insulin Delivery Devices are likely to ease the intake of insulin amongst the aging population.

Thus, the factors mentioned above, including the rising prevalence of diabetes, the increasing number of novel insulin product launches, and growing government initiatives to create awareness about diabetes and insulin use, are expected to drive the Insulin Market Value over the forecast period.

Insulin Drugs Industry Segmentation

As per the scope of the report, insulin is defined as a hormone that regulates the body's blood sugar level. It treats chronic diseases such as type 1 and type 2 diabetes. 

The insulin market is segmented by product type, application, delivery device, and geography. By product type, the market is segmented into rapid-acting insulin, combination insulin, long-acting insulin, and other product types. By application, the market is segmented by type 1 diabetes and type 2 diabetes. By delivery device, the market is segmented into pens, infusion pumps, syringes, and other delivery devices. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the above segments.

By Product Type
Rapid-Acting Insulin
Insulin Lispro
Insulin Aspart
Insulin Glulisine
Technosphere insulin
Combination Insulin
NPH/Regular
Protamine/Lispro
Protamine/Aspart
Long-Acting Insulin
Insulin Detemir
Insulin Glargine
Insulin Glargine-yfgn
Insulin Degludec
Others
By Application
Type 1 Diabetes
Type 2 Diabetes
By Delivery Device
Pens
Infusion Pumps
Syringes
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Human Insulin Drugs Market Size Summary

The human insulin market is poised for growth, driven by the increasing prevalence of diabetes and the critical role of insulin in managing this condition. The market is experiencing a steady expansion, with North America, particularly the United States, leading due to its high diabetes rates linked to sedentary lifestyles. The U.S. market is significant for insulin manufacturers, with a substantial portion of revenues generated from this region. The dominance of long-acting insulins like Lantus and Humalog underscores the importance of the U.S. market in the global landscape. The absence of generic competitors in the traditional North American insulin market further solidifies its growth prospects. The market's expansion is also supported by the ongoing development of innovative insulin formulations and delivery methods, such as oral insulin, which promise to enhance patient adherence and treatment outcomes.

The global human insulin market is characterized by a high level of consolidation, with a few major players maintaining a strong presence worldwide. Companies like Novo Nordisk, Eli Lilly, and Sanofi are at the forefront, engaging in strategic alliances and product innovations to strengthen their market positions. Recent developments, such as Eli Lilly's introduction of a biosimilar insulin at a reduced cost and Novo Nordisk's advancements in insulin injection trials, highlight the dynamic nature of the market. The focus on developing more convenient and effective insulin delivery systems, including oral formulations, reflects the industry's commitment to improving diabetes management. As the market continues to evolve, these factors are expected to drive sustained growth and transformation in the human insulin sector.

Explore More

Human Insulin Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Diabetes

      2. 1.2.2 Growing Government Initiatives to Create Awareness About Diabetes

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Requirements for Product Approval

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Product Type

      1. 2.1.1 Rapid-Acting Insulin

        1. 2.1.1.1 Insulin Lispro

        2. 2.1.1.2 Insulin Aspart

        3. 2.1.1.3 Insulin Glulisine

        4. 2.1.1.4 Technosphere insulin

      2. 2.1.2 Combination Insulin

        1. 2.1.2.1 NPH/Regular

        2. 2.1.2.2 Protamine/Lispro

        3. 2.1.2.3 Protamine/Aspart

      3. 2.1.3 Long-Acting Insulin

        1. 2.1.3.1 Insulin Detemir

        2. 2.1.3.2 Insulin Glargine

        3. 2.1.3.3 Insulin Glargine-yfgn

        4. 2.1.3.4 Insulin Degludec

      4. 2.1.4 Others

    2. 2.2 By Application

      1. 2.2.1 Type 1 Diabetes

      2. 2.2.2 Type 2 Diabetes

    3. 2.3 By Delivery Device

      1. 2.3.1 Pens

      2. 2.3.2 Infusion Pumps

      3. 2.3.3 Syringes

      4. 2.3.4 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Human Insulin Drugs Market Size FAQs

The Human Insulin Drugs Market size is expected to reach USD 27.96 billion in 2024 and grow at a CAGR of 3.87% to reach USD 33.81 billion by 2029.

In 2024, the Human Insulin Drugs Market size is expected to reach USD 27.96 billion.

Insulin Market Report Snapshots

Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024-2029) (2024 - 2029)